Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

Natalizumab, a therapeutic monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), is recommended to be withdrawn 3 months prior to a planned pregnancy. Our aim was to analyse the safety and impact of natalizumab exposure on course of disease and pregnancy outcome.Prospective follow-up of women with MS who became accidentally pregnant during natalizumab treatment in comparison with pregnancies of women...